Whether modulation of hBD-1 expression, e.g., by NR-agonist treatment, is a relevant target to optimize treatment of cholestatic liver diseases merits further pre-clinical and clinical evaluation. The gene discussed is DEFB1; the disease is Cholestatic liver disease.